Selumetinib in uveal melanoma

In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumour response rate, but no improvement in overall survival, according to a study in JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events. Read more here.